Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

984 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.
Kroep JR, Smit EF, Giaccone G, Van der Born K, Beijnen JH, Van Groeningen CJ, Van der Vijgh WJ, Postmus PE, Pinedo HM, Peters GJ. Kroep JR, et al. Among authors: giaccone g. Cancer Chemother Pharmacol. 2006 Oct;58(4):509-16. doi: 10.1007/s00280-006-0191-z. Epub 2006 Mar 7. Cancer Chemother Pharmacol. 2006. PMID: 16523337 Clinical Trial.
Update on the systemic treatment of lung cancer.
Giaccone G, Smit EF. Giaccone G, et al. Cancer Chemother Biol Response Modif. 2002;20:697-716. Cancer Chemother Biol Response Modif. 2002. PMID: 12703231 Review. No abstract available.
Lung cancer.
Giaccone G, Smit E. Giaccone G, et al. Cancer Chemother Biol Response Modif. 2003;21:445-83. doi: 10.1016/s0921-4410(03)21022-x. Cancer Chemother Biol Response Modif. 2003. PMID: 15338759 Review. No abstract available.
Lung cancer.
Giaccone G, Smit E. Giaccone G, et al. Cancer Chemother Biol Response Modif. 2005;22:413-42. doi: 10.1016/s0921-4410(04)22019-1. Cancer Chemother Biol Response Modif. 2005. PMID: 16110623 Review. No abstract available.
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D'Incecco A, Smit EF, Falcone A, Burgers JA, Santoro A, Danesi R, Giaccone G, Tibaldi C. Giovannetti E, et al. Among authors: giaccone g. Mol Cancer Ther. 2010 Mar;9(3):581-93. doi: 10.1158/1535-7163.MCT-09-0665. Epub 2010 Feb 16. Mol Cancer Ther. 2010. PMID: 20159991 Free article.
984 results